NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 12:55
Last Report Issued 07/01/2016 08:47

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 3080U-POS
Patient ID 3080U-POS
Chain 16000949
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 16000949

Received 07/01/2016 08:20

Sample ID 16000949-001
Matrix Urine
Patient Name 3080U-POS
Patient ID 3080U-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
3080U MOCA, Urine				
Analysis by Refractometer (REF)				
Specific Gravity	2.100			ELEVATED
Physiologic range: 1.010 - 1.030. Samples with Specific Gravity lower than 1.010 are too dilute and should be recollected.				
Analysis by Gas Chromatography/Mass Spectrometry (GC/MS)				
MOCA	5.0	ng/mL	0.20	
Synonym(s): Methylene Orthochloroaniline				
Workers exposed to air concentrations that generally averaged less than 0.01 mg/cubic meter over a 12 month period exhibited urine MOCA concentrations that averaged 160 - 1260 ng/mL, with individual maximum levels as high as 6700 ng/mL.				
MOCA (Specific Gravity corrected)	0.10	ng/mL	0.0043	

Results for sample 16000949-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 16000949-001
Matrix Urine
Patient Name 3080U-POS
Patient ID 3080U-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
California OSHA has determined that employees whose urinary levels of MOCA exceed 100 ng/mL with Specific Gravity adjusted to 1.024 shall be tested at least monthly until 2 consecutive samples, taken no less than 3 days apart, have been reduced to below 100 ng/mL.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.